Orchestra BioMed Holdings, Inc. Changes in Estimated Future Development Costs
Orchestra BioMed Holdings, Inc. (OBIO) reported Changes in Estimated Future Development Costs of $30.00 million for the 12-month period ending 2019-12-31, per its 10-Q filed 2023-05-12.
Discontinued › Cash Flow › Operating Activities
srt:IncreaseDecreaseInEstimatedFutureDevelopmentCosts · last filed 2023-05-12
| Period end | Changes in Estimated Future Development Costs 1 month | Changes in Estimated Future Development Costs 12 month |
|---|---|---|
| 2019-12-31 | $30.00M 10-Q · filed 2023-05-12 | |
| 2019-06-30 | $65.00M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |